


NOW RECRUITING
Newly Diagnosed **FLT3-ITD (+) AML**
in Patients **aged 18 - 75**

QuANTUM-FIRST STUDY

Quizartinib Advancement into the Next Generation of Trials for Unmet Needs in AML

A Phase 3, Randomized, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed **FLT3-ITD (+) Acute Myeloid Leukemia**



Primary Endpoint: Event-free Survival (EFS)

Secondary Endpoints:

- Overall Survival (OS)
- Composite Complete Remission (CRc)
- Complete Remission (CR)
- CR with no evidence of minimal residual disease (MRD)

Location: North America, Europe, Asia/Other Regions | **ClinicalTrials.gov Identifier:** NCT02668653

Quizartinib is an investigational agent and is not approved by the FDA or other regulatory agencies worldwide as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that quizartinib will become commercially available.

For more information about this clinical trial, please visit
www.clinicaltrials.gov/ct2/show/results/NCT02668653

 **Daiichi-Sankyo**

Passion for Innovation.
Compassion for Patients.™